Cargando…
Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data
Trachoma is an infectious disease characterized by repeated exposures to Chlamydia trachomatis (Ct) that may ultimately lead to blindness. Efficient identification of communities with high infection burden could help target more intensive control efforts. We hypothesized that IgG seroprevalence in c...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942265/ https://www.ncbi.nlm.nih.gov/pubmed/35275911 http://dx.doi.org/10.1371/journal.pntd.0010273 |
_version_ | 1784673269345943552 |
---|---|
author | Tedijanto, Christine Aragie, Solomon Tadesse, Zerihun Haile, Mahteme Zeru, Taye Nash, Scott D. Wittberg, Dionna M. Gwyn, Sarah Martin, Diana L. Sturrock, Hugh J. W. Lietman, Thomas M. Keenan, Jeremy D. Arnold, Benjamin F. |
author_facet | Tedijanto, Christine Aragie, Solomon Tadesse, Zerihun Haile, Mahteme Zeru, Taye Nash, Scott D. Wittberg, Dionna M. Gwyn, Sarah Martin, Diana L. Sturrock, Hugh J. W. Lietman, Thomas M. Keenan, Jeremy D. Arnold, Benjamin F. |
author_sort | Tedijanto, Christine |
collection | PubMed |
description | Trachoma is an infectious disease characterized by repeated exposures to Chlamydia trachomatis (Ct) that may ultimately lead to blindness. Efficient identification of communities with high infection burden could help target more intensive control efforts. We hypothesized that IgG seroprevalence in combination with geospatial layers, machine learning, and model-based geostatistics would be able to accurately predict future community-level ocular Ct infections detected by PCR. We used measurements from 40 communities in the hyperendemic Amhara region of Ethiopia to assess this hypothesis. Median Ct infection prevalence among children 0–5 years old increased from 6% at enrollment, in the context of recent mass drug administration (MDA), to 29% by month 36, following three years without MDA. At baseline, correlation between seroprevalence and Ct infection was stronger among children 0–5 years old (ρ = 0.77) than children 6–9 years old (ρ = 0.48), and stronger than the correlation between active trachoma and Ct infection (0-5y ρ = 0.56; 6-9y ρ = 0.40). Seroprevalence was the strongest concurrent predictor of infection prevalence at month 36 among children 0–5 years old (cross-validated R(2) = 0.75, 95% CI: 0.58–0.85), though predictive performance declined substantially with increasing temporal lag between predictor and outcome measurements. Geospatial variables, a spatial Gaussian process, and stacked ensemble machine learning did not meaningfully improve predictions. Serological markers among children 0–5 years old may be an objective tool for identifying communities with high levels of ocular Ct infections, but accurate, future prediction in the context of changing transmission remains an open challenge. |
format | Online Article Text |
id | pubmed-8942265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-89422652022-03-24 Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data Tedijanto, Christine Aragie, Solomon Tadesse, Zerihun Haile, Mahteme Zeru, Taye Nash, Scott D. Wittberg, Dionna M. Gwyn, Sarah Martin, Diana L. Sturrock, Hugh J. W. Lietman, Thomas M. Keenan, Jeremy D. Arnold, Benjamin F. PLoS Negl Trop Dis Research Article Trachoma is an infectious disease characterized by repeated exposures to Chlamydia trachomatis (Ct) that may ultimately lead to blindness. Efficient identification of communities with high infection burden could help target more intensive control efforts. We hypothesized that IgG seroprevalence in combination with geospatial layers, machine learning, and model-based geostatistics would be able to accurately predict future community-level ocular Ct infections detected by PCR. We used measurements from 40 communities in the hyperendemic Amhara region of Ethiopia to assess this hypothesis. Median Ct infection prevalence among children 0–5 years old increased from 6% at enrollment, in the context of recent mass drug administration (MDA), to 29% by month 36, following three years without MDA. At baseline, correlation between seroprevalence and Ct infection was stronger among children 0–5 years old (ρ = 0.77) than children 6–9 years old (ρ = 0.48), and stronger than the correlation between active trachoma and Ct infection (0-5y ρ = 0.56; 6-9y ρ = 0.40). Seroprevalence was the strongest concurrent predictor of infection prevalence at month 36 among children 0–5 years old (cross-validated R(2) = 0.75, 95% CI: 0.58–0.85), though predictive performance declined substantially with increasing temporal lag between predictor and outcome measurements. Geospatial variables, a spatial Gaussian process, and stacked ensemble machine learning did not meaningfully improve predictions. Serological markers among children 0–5 years old may be an objective tool for identifying communities with high levels of ocular Ct infections, but accurate, future prediction in the context of changing transmission remains an open challenge. Public Library of Science 2022-03-11 /pmc/articles/PMC8942265/ /pubmed/35275911 http://dx.doi.org/10.1371/journal.pntd.0010273 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Tedijanto, Christine Aragie, Solomon Tadesse, Zerihun Haile, Mahteme Zeru, Taye Nash, Scott D. Wittberg, Dionna M. Gwyn, Sarah Martin, Diana L. Sturrock, Hugh J. W. Lietman, Thomas M. Keenan, Jeremy D. Arnold, Benjamin F. Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
title | Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
title_full | Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
title_fullStr | Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
title_full_unstemmed | Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
title_short | Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
title_sort | predicting future community-level ocular chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942265/ https://www.ncbi.nlm.nih.gov/pubmed/35275911 http://dx.doi.org/10.1371/journal.pntd.0010273 |
work_keys_str_mv | AT tedijantochristine predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT aragiesolomon predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT tadessezerihun predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT hailemahteme predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT zerutaye predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT nashscottd predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT wittbergdionnam predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT gwynsarah predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT martindianal predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT sturrockhughjw predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT lietmanthomasm predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT keenanjeremyd predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata AT arnoldbenjaminf predictingfuturecommunitylevelocularchlamydiatrachomatisinfectionprevalenceusingserologicalclinicalmolecularandgeospatialdata |